<code id='9D248166F6'></code><style id='9D248166F6'></style>
      • <acronym id='9D248166F6'></acronym>
      <center id='9D248166F6'><center id='9D248166F6'><tfoot id='9D248166F6'></tfoot></center><abbr id='9D248166F6'><dir id='9D248166F6'><tfoot id='9D248166F6'></tfoot><noframes id='9D248166F6'>
      • <optgroup id='9D248166F6'><strike id='9D248166F6'><sup id='9D248166F6'></sup></strike><code id='9D248166F6'></code></optgroup>
        5. <b id='9D248166F6'><label id='9D248166F6'><select id='9D248166F6'><dt id='9D248166F6'><span id='9D248166F6'></span></dt></select></label></b><u id='9D248166F6'></u>
          <i id='9D248166F6'><strike id='9D248166F6'><tt id='9D248166F6'><pre id='9D248166F6'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          knowledge 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          knowledge  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：332
                                  
                                    
          
                                    
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          When is a doctor not a doctor? Try when patients address women doctors
                                
                            
          Next article：  
                                      
                                          Medical records are filled with copy
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          explore
          
                  
          

                    
          
            
          
              
                After affirmative action ruling, medical educators look to 'holistic review'
                
          
                        
              
          
                After affirmative action ruling, medical educators look to 'holistic review'
                
          
                  
          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                New case study details death in closely watched Alzhiemer's trial
                
          
                        
              
          
                New case study details death in closely watched Alzhiemer's trial
                
          
                  
          AbrainaffectedbyAlzheimer'sdisease,attheMuseumofNeuroanatomyattheUniversityatBuffalo.DavidDuprey/API
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                DIEP, the 'gold standard' of breast reconstruction, is under threat
                
          
                        
              
          
                DIEP, the 'gold standard' of breast reconstruction, is under threat
                
          
                  
          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          Why is France rioting? What to know about the fatal police shooting of Nahel M
          
            
          1:17FrenchpoliceofficerspatrolinfrontoftheArcdeTriompheintheChampsElyseesareaofParis,France,onJuly1,
          
          
          
          
          
            read more